



UNIVERSITY OF WASHINGTON
Office of Animal Welfare

DATE: September 28, 2020

TO: Cystic Fibrosis Foundation

SUBJECT: Notice of Institutional Animal Care and Use Committee Approval

The following application has been reviewed and the associated IACUC protocol is approved. The grant/contract and the associated IACUC protocol are concordant in terms of animal use.

Principal Investigator: Pradeep Singh

eGC1: A160477

Project Title: UW RDP – Center for Basic and Translational Research in Cystic Fibrosis Respiratory Disease

Protocol Number: 4503-01

Protocol Approval Dates: 9/28/2020 - 9/27/2023

Note: This approval is for a new project (Abuzeid) under the parent award SINGH19R0 (eGC1160477).
Additionally, timing of endoscopic cultures differs between the grant proposal and protocol.
Cultures will occur at the frequency described in the protocol.

The project as proposed meets the standards of the Guide for the Care and Use of Laboratory Animals and applicable University policies and procedures. The University of Washington has an approved Animal Welfare Assurance (#A3464-01) on file with the NIH Office of Laboratory Animal Welfare (OLAW), and the University is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International.

A handwritten signature in cursive script, reading "A Schoenleben".

Aubrey Schoenleben, PhD
Review Scientist, Institutional Animal Care and Use Committee
Office of Animal Welfare
University of Washington, Box 357160
Seattle, WA 98195-7160
Phone: 206.685.6923, Fax: 206.616.5664

From: Crist, Donna <donna.crist@seattlechildrens.org>
Sent: Monday, July 20, 2020 11:22 AM
To: Aubrey Schoenleben
Subject: RE: Singh CF RDP | A160477 | Pradeep Singh - OAW Concurrence Letter Request
Attachments: CFF SINGH19R0 Regulatory Summary Jul 2020_v2.doc; eGC1 A40995 (Bellairs) - Approval.pdf

Thanks Aubrey – this is perfect. For all Cystic Fibrosis Foundation awarded grants, they require copies of all regulatory approvals, (IRB, IACUC and BUAL) so we do need updated letters with each new renewal. They have even withheld payments when approvals expire mid-fiscal year so I occasionally have to submit revised approvals outside of the annual progress report submission.

I agree that having individual approvals is probably best as we do have projects start and stop at varying times through the life of this award so it's easiest to link approvals to individual projects versus all lumped under the parent and eGC1.

Thanks for understanding and I apologize for the added burden this causes OAW. I do track these approvals on a master sheet which I've attached. This allows me to know when one of our regulatory documents will be expiring so I can be sure to obtain the updated version for our files.

Best,

Donna Crist

Program Manager, Cystic Fibrosis Research Center
Seattle Children's Hospital and Research Institute
University of Washington

206-884-7544 OFFICE
206-349-6636 CELL – please use during COVID-19 outbreak

OFFICE 2001 Eighth Ave, Suite 500; Seattle, WA 98121
MAIL M/S CW8-5B

donna.crist@seattlechildrens.org

From: Aubrey Schoenleben <aubreys@uw.edu>
Sent: Monday, July 20, 2020 10:50 AM
To: Crist, Donna <donna.crist@seattlechildrens.org>
Subject: Re: Singh CF RDP | A160477 | Pradeep Singh - OAW Concurrence Letter Request

Hi Donna,

Attached is an updated approval letter for the Bellairs project using the original eGC1 number (A140995). Though we typically like to write a single approval letter that includes all protocols associated with a given eGC1, I think given the nature of this grant, it may be easier to issue approval letters individually as new projects come online. I've made a note of this on the approval letter. I'll send a separate letter once Dr. Abuzeid's protocol is approved.

With regards to the new eGC1, we (OAW) no longer issue updated approval letters for non-competing renewals unless requested by the sponsor. More than happy to do so if its needed. Just let me know.

Thanks (and apologies for the confusion!),
Aubrey

From: Crist, Donna <donna.crist@seattlechildrens.org>
Sent: Thursday, July 16, 2020 9:27 AM
To: Aubrey Schoenleben <aubreys@uw.edu>
Subject: RE: Singh CF RDP | A160477 | Pradeep Singh - OAW Concurrence Letter Request

Great – thanks for the protocol number. If you are able to provide a concurrently letter with the eGC1 linked to our currently award (A140995), that would be great. I know OAW likes to submit a single concurrently letter with all protocols for a given eGC1 on a single letter so perhaps once you finish the review of Dr. Abuzeid's protocol, you could write a letter that include both his project and Dr. Bellairs/Raible's fellowship for the new eGC1 A160477.

Thanks,
Donna

From: Aubrey Schoenleben <aubreys@uw.edu>
Sent: Thursday, July 16, 2020 8:10 AM
To: Crist, Donna <donna.crist@seattlechildrens.org>
Subject: Re: Singh CF RDP | A160477 | Pradeep Singh - OAW Concurrence Letter Request

Thanks for the clarification, Donna! An email sent to OAWRSS earlier this week suggested that you needed the concurrence letter under the new eGC1, which is why I included it. More than happy to send a revised letter under the parent eGC1 if needed. Just let me know.

Also, thank you for the heads up re: Dr. Abuzeid's project. I am actually in the middle of reviewing that protocol this week, so your timing is perfect! His protocol number will be 4502-01.

Cheers,
Aubrey

From: Crist, Donna <donna.crist@seattlechildrens.org>
Sent: Wednesday, July 15, 2020 5:05 PM
To: Aubrey Schoenleben <aubreys@uw.edu>
Subject: FW: Singh CF RDP | A160477 | Pradeep Singh - OAW Concurrence Letter Request

Thanks so much Aubrey. Just as a sidenote, this project was awarded under eGC1 140995 with funding through 9/30/20. eGC1 A160477 is for the upcoming Progress Report which will cover funding starting 10/1/20. While I can probably use the attached concurrence review to cover this project under both funding periods, I just wanted to clarify that for you.

Also, there is another newly approved project being included in the progress report under eGC1 A160477 that will use rabbits. It's under Waleeb Abuzeid and I have attached his application that was just approved for funding.

His project and funding does not begin until 10/1/20 but we will need a similar concurrence letter for his project to include with our upcoming progress report (which is due 9/1/20). I have not linked that project to this eGC1

yet as I do not have a protocol number. Please let me know if one has been assigned for this project so I can add that to the eGC1.

Best,

Donna Crist

Program Manager, Cystic Fibrosis Research Center
Seattle Children's Hospital and Research Institute
University of Washington

206-884-7544 OFFICE
206-349-6636 CELL – please use during COVID-19 outbreak

OFFICE 2001 Eighth Ave, Suite 500; Seattle, WA 98121
MAIL M/S CW8-5B

donna.crist@seattlechildrens.org

From: Aubrey Schoenleben <aubreys@uw.edu>
Sent: Wednesday, July 15, 2020 2:50 PM
To: Edwin W Rubel <rubel@uw.edu>
Cc: Joseph Bellairs (External) <jbellai@uw.edu>; David W. Raible <draible@uw.edu>; Robin Gibson <rgibson@uw.edu>; Lisa Caprina <caprina@uw.edu>; Crist, Donna <donna.crist@seattlechildrens.org>
Subject: Re: Singh CF RDP | A140995 | Pradeep Singh - IAW Concurrence Letter Request

Hi all,

Just passing along an update. Both amendments came out of committee review without any questions, and were approved today. I've also finalized approval of the related grant and uploaded the congruence letter to HoverBoard. I've attached a copy here as well for ease of reference.

Please let me know if you have questions or if I can be of further assistance.

Have a good afternoon,
Aubrey

From: Aubrey Schoenleben <aubreys@uw.edu>
Sent: Tuesday, July 7, 2020 8:31 AM
To: Edwin W Rubel <rubel@uw.edu>
Cc: Jo Bellairs <jbellai@uw.edu>; David W. Raible <draible@uw.edu>; Robin Gibson <rgibson@uw.edu>
Subject: Re: Singh CF RDP | A140995 | Pradeep Singh - IAW Concurrence Letter Request

Thanks, Dr. Rubel! I will get the amendment submitted today. It looks like the changes that you made were all very minor, so I do not have any pre-review questions. I will send the amendment directly to vet review. Since the amendment is associated with a new grant, I will mark it as a priority so that it makes it's way through the review process as quickly as possible.

In the meantime, please don't hesitate to get in touch with questions.

Cheers,
Aubrey

From: Edwin W Rubel <rubel@uw.edu>
Sent: Monday, July 6, 2020 3:40 PM
To: Aubrey Schoenleben <aubreys@uw.edu>
Cc: Jo Bellairs <jbellai@uw.edu>; David W. Raible <draible@uw.edu>; Robin Gibson <rgibson@uw.edu>
Subject: Re: Singh CF RDP | A140995 | Pradeep Singh - IAW Concurrence Letter Request

Hi Aubrey

We are quite happy with this version. If you can go ahead and submit it. That would be great.

I'm sure Robin can be involved if need be.

Thanks again for your help. This is a big change that will make our in vitro work much easier to initiate. It was a very good idea.

Ed

Edwin W Rubel
Professor Emeritus
Virginia Merrill Bloedel Hearing Research Center
University of Washington
<http://depts.washington.edu/rubelab/>

On 7/6/20, 10:46 AM, "Robin Gibson" <rgibson@uw.edu> wrote:rgibson@uw.edu

Hi Ed.

Jo and I have reviewed the amendment and both of us are fine with it.

If Aubrey can submit it on our behalf that would be great.

Thanks.

Robin

Robin M. Gibson, Ph.D.
Department of Otolaryngology
Virginia Merrill Bloedel Hearing Research Center
CHDD CD176F Box 357923
University of Washington
Seattle, WA 98195-7923
Telephone: 206-221-6438
FAX: 206-221-5685



UNIVERSITY OF WASHINGTON
Office of Animal Welfare

DATE: July 15, 2020

TO: Cystic Fibrosis Foundation

SUBJECT: Notice of Institutional Animal Care and Use Committee Approval

The following application has been reviewed and the associated IACUC protocols are approved. The grant/contract and the associated IACUC protocols are concordant in terms of animal use.

Principal Investigator: Pradeep Singh

eGC1: A140995

Project Title: UW RDP – Center for Basic and Translational Research in Cystic Fibrosis Respiratory Disease

IACUC Protocol Number	Approval Dates
2048-02	3/9/2018 – 3/8/2021; amendment approved 7/15/2020
2997-01	9/16/2019 – 9/15/2022; amendment approved 7/15/2020

Note: This approval is for a new project (Bellairs) under the parent award SINGH19R0 (eGC1 A140995). Additionally, the compound being evaluated as part of this work, ORC-13661, was previously known as PROTO-13661. The compound is referenced by its old name in protocol 2997-01.

The project as proposed meets the standards of the Guide for the Care and Use of Laboratory Animals and applicable University policies and procedures. The University of Washington has an approved Animal Welfare Assurance (#A3464-01) on file with the NIH Office of Laboratory Animal Welfare (OLAW), and the University is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International.

Aubrey Schoenleben, PhD
Review Scientist, Institutional Animal Care and Use Committee
Office of Animal Welfare
University of Washington, Box 357160
Seattle, WA 98195-7160
Phone: 206.685.6923, Fax: 206.616.5664

On Jul 6, 2020, at 9:12 AM, Aubrey Schoenleben <aubreys@uw.edu> wrote:

Hi Dr. Rubel,

Thank you for the apology - much appreciated! Please let me know if you or your team have any questions as you are getting the final version of the amendment together.

Cheers,
Aubrey

Sent from my iPhone

On Jul 2, 2020, at 11:52 AM, Edwin W Rubel <rubel@uw.edu> wrote:

Dear Aubrey

First, Let me apologize for my overly critical comments in our telephone conversation on Tuesday. I'm sorry to have sounded so annoyed and recognize that you were trying to do your job.

Second, thank you very much for providing this draft of a general solution to our problems of trying to use in vitro studies of mammalian inner ear studies examining toxicity and protection of inner ear tissues from mice.

In the next day or two I will make some small wording changes and pass it along to my colleagues on this project for their suggestion and then inform you of a final version (marked "Final") . We appreciate your willingness to insert it into Hoverboard and then provide approval, and I ask you to work with Robin on this.

Again, thank you for doing this work on our behalf and for accepting my apology (hopefully).

Ed Rubel

Edwin W Rubel
Professor Emeritus
Virginia Merrill Bloedel Hearing Research Center

University of Washington

<http://depts.washington.edu/rubelab/>

On 7/1/20, 11:25 AM, "Aubrey Schoenleben" <aubreys@uw.edu>
wrote:aubreys@uw.edu

Hi Dr. Rubel,

How are you? Following up on our conversation from yesterday, attached is a draft of how we can modify Experiment 004 of your mouse protocol to be more flexible. Please take a look and let me know if you have questions, edits or would like to discuss further. If its helpful, once we settle on a final version of the amendment, I would be happy to enter it in to HoverBoard and submit it on your behalf. Just let me know.

Thanks,
Aubrey

From: Aubrey Schoenleben <aubreys@uw.edu>
Sent: Tuesday, June 30, 2020 3:22 PM
To: Edwin W Rubel <rubel@uw.edu>
Cc: David W. Raible <draible@uw.edu>; Robin Gibson <rgibson@uw.edu>; Jo Bellairs <jabellai@uw.edu>
Subject: Re: Singh CF RDP | A140995 | Pradeep Singh - IAW Concurrence Letter Request

Sure thing, Dr. Rubel - I will give you a call shortly.
Aubrey

From: Edwin W Rubel <rubel@uw.edu>
Sent: Tuesday, June 30, 2020 3:16 PM
To: Aubrey Schoenleben <aubreys@uw.edu>
Cc: David W. Raible <draible@uw.edu>; Robin Gibson <rgibson@uw.edu>; Jo Bellairs <jabellai@uw.edu>
Subject: Re: Singh CF RDP | A140995 | Pradeep Singh - IAW Concurrence Letter Request

Dear Aubrey

Please call me at your earlies convenience



RCW 42.56.250(4)

Ed Rubel

Edwin W Rubel
Professor Emeritus
Virginia Merrill Bloedel Hearing Research Center
University of Washington
<http://depts.washington.edu/rubelab/>

On 6/30/20, 3:01 PM, "Aubrey Schoenleben" <aubreys@uw.edu>
wrote:aubreys@uw.edu

Hi Jo,

Thank you for the update. I do think that we need to update the Rubel protocol for congruence. The experiment in the protocol is currently written very specifically (e.g., it asks how the inhibition of calcium through Atp2b2a channels affects the toxicity of aminoglycoside antibiotics, which is a different question/purpose than what you will be using the cochlear cultures for). For this amendment, we can either add your work as a third bullet point to that experiment, or we can revise the experiment so that the language is more flexible and can cover a broader range of experiments. Either option should be a very straight forward update.

Please let me know if you need help getting either amendment together.

Thanks,
Aubrey

From: Jo Bellairs <jbellai@uw.edu>
Sent: Monday, June 22, 2020 4:16 PM
To: Aubrey Schoenleben <aubreys@uw.edu>
Cc: David W. Raible <draible@uw.edu>; Edwin W Rubel <rubel@uw.edu>; Robin Gibson <rgibson@uw.edu>
Subject: Re: Singh CF RDP | A140995 | Pradeep Singh - IAW Concurrence Letter Request

Hi Aubrey,

Thank you very much for your help reviewing my grant and generating the IAW letter of concurrence. I have discussed your questions with Dr. Rubel (mouse experiments) and Dr. Raible (zebrafish experiments) and we have come up with the following answers. Please do not hesitate to reach out with any questions, concerns, or comments!

- Aim 1, Exp 1 (zebrafish). Dr. Raible and I will submit a new experimental

protocol that includes UV light exposure.

- Aim 1, Exp 2 (mice). Dr. Rubel pointed out that all of the proposed mutants in the current protocol are on a C57/Bl6 background, and therefore wildtype mice are implicitly included as controls. He also pointed out that because of mendelian ratios, half of all breeding will produce wildtype pups. He feels that no additional animal numbers are needed, but please let us know if you feel differently.
- Aim 2, Exp 1 & 2 (zebrafish). For now, the animal numbers cover this proposed work. We will be sure to update our numbers as needed.

Thanks again for your help,

Jo

From: Aubrey Schoenleben <aubreys@uw.edu>

Sent: Friday, June 19, 2020 5:17 PM

To: Jo Bellairs <jbellai@uw.edu>

Cc: David W. Raible <draible@uw.edu>; Edwin W Rubel <rubel@uw.edu>

Subject: Re: Singh CF RDP | A140995 | Pradeep Singh - IAW Concurrence Letter Request

Hi Jo,

Thank you so much for the additional details - very helpful! A few follow up questions:

- Aim 1, Experiment 1 (zebrafish). The grant states that following exposure to ORC-13661, fish will be UV irradiated and then euthanized. I don't see a UV irradiation procedure on protocol 2997-01. Would this be considered part of the confocal imaging procedure? Additionally, the sequence of events described in the protocol states that fish will also be treated with an ototoxin and vital dyes prior to imaging/euthanasia. The study described in the grant currently does not include these additional treatment steps. Has the plan for this study changed to include these additional steps? Okay if it has, we just need to document this in the approval letter. Alternately, if these steps will not be included in your work, then we should modify the language in the protocol to be more flexible (i.e., some of the steps outlined are optional).
- Aim 1, Experiment 2 (mice). Yes, this experiment does describe euthanasia of mice for cochlear culture, however, the experiment is currently written quite specifically in terms of the strains of mice that will be used for this work (Deafwaddler-i5 mutants, Sigmar1 mutants, various Ai96/myoXV-cre genotypes). The grant application states that wildtype (C57/Bl6) mice will be used for this study. Is that still the plan, or will one of these other strains be used instead? If the plan is to still use wildtype mice for these studies, we will need to modify this experiment to include this strain and the related animal numbers.
- Aim 2, Experiment 1 and 2 (zebrafish). Looks like the experimental

sequences are covered in the protocol. Just wanted to confirm that additional animals are not needed to support the new work being added with the grant.

Please let me know if you have questions or if it would be helpful to discuss any of the above via phone.

Have a great weekend,
Aubrey

From: Jo Bellairs <jabellai@uw.edu>
Sent: Monday, June 15, 2020 10:25 AM
To: Aubrey Schoenleben <aubreys@uw.edu>
Cc: David W. Raible <draible@uw.edu>; Edwin W Rubel <rubel@uw.edu>
Subject: Re: Singh CF RDP | A140995 | Pradeep Singh - IAW Concurrence Letter Request

Hi Aubrey,

Thank you again for the help with IAW concurrence for this grant. Please see below for a summary of the proposed work and the relevant protocols and experiments for that work.

As a point of clarification, please note that this work revolves around investigations using the compound ORC-13661 and structurally related analogues. Previously, ORC-13661 was known as PROTO-13661. ORC-X and PROTO-X are interchangeable, and the compounds used in the proposed work are all considered PROTO-1 analogues.

AIM 1: Target localization

- Experiment 1: zebrafish will be treated with ORC-13661 analogues and imaged to identify fluorescently labeled target.
 - Please see protocol 2997-01, Experiment 08. Hair Cell protection. This protocol covers in vivo treatment of zebrafish with numerous compounds, including ORC-13661 analogues (Substance Administration: Raible Lab: Otoprotectants, ver 2: PROTO-1 analogues (PROTO-X or PROTO1/2 like), and imaging these zebrafish.
- Experiment 2: tissue collected from neonatal mice will be labeled with ORC-13661 analogues and imaged.
 - Please see protocol 2048-02, Experiment 04. Genetic modulation of aminoglycoside ototoxicity. This experiment requires tissue to be obtained from P2 mice. Mice will not be treated or manipulated in any way prior to euthanasia and tissue collection as detailed in the experimental protocol of Experiment 04.

AIM 2: Target Identification

- Experiment 1: protein collection for proteomics work.
 - Please see protocol 2997-01, Experiment 18: protein isolation from zebrafish. his protocol covers in vivo treatment of zebrafish with numerous compounds, including ORC-13661 analogues (Substance Administration: Raible Lab: Otoprotectants, ver 2: PROTO-1 analogues (PROT-X or PROTO1/2 like), followed by euthanasia.
- Experiment 2: targeted mutagenesis with CRISPR in zebrafish
 - Please see protocol 2997-01, Experiment 04: Genetic screening: CRISPR. This protocol covers generating transgenic zebrafish through well established CRISPR protocols.

Please do not hesitate to reach out with any additional questions, or if I can provide any further clarification.

Sincerely,
Jo

From: Aubrey Schoenleben <aubreys@uw.edu>
Sent: Friday, June 12, 2020 1:15 PM
To: Jo Bellairs <jbellai@uw.edu>
Cc: David W. Raible <draible@uw.edu>; Edwin W Rubel <rubel@uw.edu>
Subject: Re: Singh CF RDP | A140995 | Pradeep Singh - IAW Concurrence Letter Request

Hi Dr. Bellairs,

How are you? I am completing the side by side review of your new fellowship grant (congrats!) and the related animal protocols. I currently do not see the studies described in the grant on either protocol (2997-02, 2048-02). Could you please let me know which experiments in particular cover the work described in the grant? Alternately, if you know that an amendment is needed to one/both protocols, please submit at your convenience.

Please don't hesitate to get in touch with questions or if you'd like to discuss further.

Thanks,
Aubrey

On 6/4/20, 3:28 PM, "Jennifer Freeling Iwamoto" <jpf2@uw.edu> wrote:

Good afternoon, team.

Could you please put this eGC1 and the attached Fellowship Application, as well as a copy of this email, into the grant workroom? It's a pilot/fellowship grant, so projects are added mid-cycle. Looks like this project cites Raible 2997-01 and Rubel 2048-02.

Including Aubrey and Kelly because you guys are the liaisons for Raible and Rubel, respectively (yay alliteration!). Do either of you have bandwidth for this? Just asking

because you're the liaisons, but I don't mind taking it if you're busy.

Thanks!

-Jenny

From: Crist, Donna <donna.crist@seattlechildrens.org>
Sent: Thursday, June 4, 2020 11:14 AM
To: Jennifer Freeling Iwamoto <jpf2@uw.edu>
Cc: Jo Bellairs <jabellai@uw.edu>; David W. Raible <draible@uw.edu>; Richard S. Sewell <sewellrs@uw.edu>
Subject: Singh CF RDP | A140995 | Pradeep Singh - IAW Concurrence Letter Request

Jennifer –

You have previously helped me with obtaining an IAW approval letter for the parent award SINGH19R0 under eGC1 A140995. Because the Cystic Fibrosis Foundation requires us to provide formal IACUC approvals notices for all funded projects, we often have to seek these concurrence letters mid-fiscal period after the funding has started since we can fund pilot and fellowship projects mid-year.

As such, I am attaching a Fellowship application for Dr. Bellairs that was submitted to us and recently approved for funding by our Steering Committee. Dr. Bellairs provided me with the attached IACUC approvals related to this work which are under his mentor, David Raible.

Please review the proposed research plans along-side the 2 attached IACUC approvals and send me a concurrence approval letter the reflects IACUC approval of the attached fellowship application and protocols.

The parent competing renewal application under eGC1 140995 did not have any planned animal studies in that application at the time. Both a previously approved protocol under this eGC1 approval as well as this one are being funded with carryover funds that have subsequently been added to this award and therefore are only just now being awarded. As such, I am including Richard Sewell from OSP in this message as well so that he is able to link this message and the IAW approval letter to this eGC1.

Let me know if you have any questions regarding this.

Regards,

Donna Crist

Program Manager, Cystic Fibrosis Research Center
Seattle Children's Hospital and Research Institute
University of Washington

206-884-7544 OFFICE
206-349-6636 CELL – please use during COVID-19 outbreak

OFFICE 2001 Eighth Ave, Suite 500; Seattle, WA 98121

CONFIDENTIALITY NOTICE: This e-mail, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information protected by law. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

CONFIDENTIALITY NOTICE: This e-mail, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information protected by law. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

CONFIDENTIALITY NOTICE: This e-mail, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information protected by law. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

CONFIDENTIALITY NOTICE: This e-mail, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information protected by law. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

SINGH19R0 – CF Research Development Program (Pradeep Singh) eGC1 A160477
IRB/IACUC/BUAL Approvals as of Jul 2019

PI	Component	Funding period	IRB#	IRB Date	IACUC #	IACUC Date	BUA #	BUA Date
Pradeep Singh	Admin Core	10/1/19-9/30/23	NA	NA	NA	NA	NA	NA
Ron Gibson Moirra Aitken	Clinical Core	10/1/19-9/30/23	SCRI 10325 (Specimens-Gibson) UW STUDY7991 (Gen Divers-Singh) UW STUDY7985 (Specimens - Goss)	1/2/20-1/1/21 12/23/19-12/22/20 10/17/19-10/16/20	NA	NA	NA	NA
Stephen Salipante Colin Manoil	Genomics Core	10/1/19-9/30/23	NA	NA	NA	NA	UW 0692-001-004 UW 0152-001-010	9/20/17-9/20/20 7/17/19-7/17/22
Lucas Hoffman Charles Frevert	HMI core	10/1/19-9/30/23	NA	NA	NA	NA	UW 0674-001-002 UW 0506-004-004	4/15/20-4/15/23 5/17/17-5/17/20
David Sherman Rafael Hernandez	Pilot project	10/1/19-9/30/21	NA	NA	NA	NA	SCRI 1293 (Sherman) SCRI 1505 (Hernandez)	7/23/19-1/22/22 2/3/16-2/3/21
Richard James Jason Debley	Mini-Pilot	8/1/19-9/30/20	SCRI 12490 (Debley) non-CF SCRI 10325 (Specimens-Gibson)	9/9/19-9/18/20 1/2/20-1/1/21	NA	NA	SCRI 1207 (James) SCRI 1254 (Debley)	7/24/18-7/24/21 8/22/17-8/22/20
Eric Morrell	Pilot	8/1/19-7/31/21	UW 50009 (Lease)-Aim 2 UW Study 8919 (Morrell)-Aim 1 UW Study 8263 (Morrell)	7/17/18-7/16/21 2/4/20-completion 10/3/19-completion	NA	NA	NA	NA
Waleed Abuzeid	Pilot	10/1/20-9/30/22	NA	NA	4502-01	pending	Check	check
Maria Nelson Mentor: Hoffman	Trainee	7/1/19-3/31/21	SCRI 15035 (Hoffman)	9/30/19-9/29/20	NA	NA	NA	NA
Joseph Bellairs Mentor: Raible	Trainee (NEW)	6/1/20 – 9/30/21	NA	NA	2048-02 2997-01	3/9/18-3/8/21 9/16/19-9/15/22	UW 0066-001-014	7/17/19-7/16/22

Magdalena Donczew Mentor: Sherman	Trainee (pending)	pending						
---	----------------------	---------	--	--	--	--	--	--